Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 7, 2015
Pharmacy Choice - News - U.S. Pharmaceutical Industry - July 7, 2015

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/7/15 - Chung Po Liu; Denial of Hearing; Final Debarment Order
FDA bases this order on a finding that Liu was convicted of a felony for conduct relating to the importation of an article of food into the United States. In determining the appropriateness and period of Liu's debarment, FDA has considered the relevant factors listed in the FD&C Act. On August 26, 2010, Chung Po Liu pleaded guilty to the felony cri
7/7/15 - Clearance of global agreement with AstraZeneca and receipt by Innate Pharma of $250m initial payment
Innate Pharma SA today announced that the co-development and commercialization agreement with AstraZeneca on Innate Pharma's proprietary anti-NKG2A antibody, IPH2201, received HSR clearance. On June 30, 2015, Innate Pharma received the initial payment of $250 million from AstraZeneca. Listed on Euronext-Paris, Innate Pharma is based in Marseille,..
7/7/15 - CSM Appoints Michael Morse as Vice President of Finance
CSM, a leading clinical trial supply company, today announced that Michael Morse has joined the executive team as Vice President of Finance. Prior to joining CSM, Morse was the Director of Finance for Genzyme Corporation, a publicly traded, billion-dollar biopharmaceutical company. During his 10+ years at Genzyme, Morse directed the financial opera
7/7/15 - Cystic Fibrosis Foundation Recognizes FDA Approval of Orkambi [Health & Beauty Close - Up]
In a release, the Foundation noted that the FDA approved the drug for people with CF ages 12 and older who have two copies of the F508del mutation, representing 8,500 people or nearly one-third of the CF population in the United States. Orkambi was developed by Vertex Pharmaceuticals with significant clinical, scientific and funding support from th
7/7/15 - Deciphera Pharmaceuticals to Present at JMP Securities Life Sciences Conference
By a News Reporter-Staff News Editor at Cancer Weekly Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, announced that Michael D. Taylor, Ph.D., Deciphera's President and Chief Executive Officer will present a corpor
7/7/15 - ENZ, LMNX Settle Suit, VSAR Regains Velocity, CATB Hits A High
WASHINGTON- Cardiovascular Systems Inc. has received FDA clearance for its new ViperWire Advance Peripheral Guide Wire with Flex Tip for Peripheral Orbital Atherectomy Systems. Shares of Catabasis Pharmaceuticals Inc. touched a new high on Monday, with the company's drug candidate CAT-1004 receiving Fast Track designation from the FDA for the...
7/7/15 - Essential Overview of the Pharma Industry Seminar: 25th of September 2015 - London UK
Dublin- Research and Markets has announced the addition of the "An Essential Overview of the Pharma Industry" conference to their offering. This programme will give you an invaluable overview of the pharmaceutical industry, from discovery of the molecule through development to marketing. A Certificate of Attendance for Professional Development will
7/7/15 - FDA Issues Notice on Final Debarment Order for Chung Po Liu
WASHINGTON, July 7 The Department of Health and Human Services published the following notice in the Federal Register from the Food and Drug Administration:. FDA bases this order on a finding that Liu was convicted of a felony for conduct relating to the importation of an article of food into the United States. In determining the appropriateness
7/7/15 - FDA Issues Notice on Qualification of Biomarker-Plasma Fibrinogen
WASHINGTON, July 7 The Department of Health and Human Services published the following notice in the Federal Register from the Food and Drug Administration:. A Notice by the Food and Drug Administration on 07/07/2015. Department of Health and Human Services.
7/7/15 - First patient enrolled in phase III study of abicipar - Molecular Partners receives USD 15 million milestone payment
First patient enrolled in phase III study of abicipar- Molecular Partners receives USD 15 million milestone payment. Phase III clinical trial of abicipar started in line with communicated timelines Milestone payment of USD 15 million triggered to Molecular Partners First product from promising DARPin platform in phase III development.
7/7/15 - Hansen Medical Secures FDA Clearance of the Magellan 10Fr Robotic Catheter [Health & Beauty Close - Up]
Hansen Medical reported that it received U.S. Food and Drug Administration 510 clearance for its Magellan 10 Fr Robotic Catheter for use in the peripheral vasculature. The FDA clearance enables the company to initiate clinical use of the 10 Fr catheter with its customers in the United States. The company said it received CE Mark approval for the 10
7/7/15 - Ignyta Announces Collaboration with UCSF For Clinical Trial of Entrectinib; Strensiq Receives Marketing Approval for Hypophosphatasia
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 2, 2015.{ nfg} Ignyta, Inc., announced a clinical collaboration with the University of California, San Francisco, under which UCSF will study entrectinib in a proof-of-concept clinical trial in cancer patients with metastatic melanoma that is posi
7/7/15 - More Drug Companies Increasing Outsourcing Budgets; CMO Partners Spring Up as Market Thrives, According to BCC Research
BCC Research reveals in its new report that the strategies of drug manufacturers, as well as contract manufacturing organizations, are driving market growth. From a predicted five-year compound annual growth of 11.5%, this segment should reach $72 billion in 2019. North America and Europe are the leading markets for contract research.
7/7/15 - Patent Issued for Anti-Fatty Acid Amide Hydrolase-2 Antibodies and Uses
By a News Reporter-Staff News Editor at Life Science Weekly From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Ali, Janid A.; Brownell, James; Brophy, Erin; Tibbitts, Thomas T., filed on April 22, 2010, was published online on June 23, 2015. The patent's assignee for patent number 9062116 is Infinity Pharmaceutica
7/7/15 - Patent Issued for Marker Associated with Non-Alcoholic Steatohepatitis
By a News Reporter-Staff News Editor at Life Science Weekly From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Sato, Ayumi; Harada, Tsuyoshi; Yano, Takashi; Wakabayashi, Yoko, filed on October 15, 2010, was published online on June 23, 2015. The patent's assignee for patent number 9060981 is MOCHIDA PHARMACEUTICAL
7/7/15 - Provectus partners with big pharma for its PV-10 drug [The Knoxville News-Sentinel, Tenn.]
July 07 Provectus Biopharmaceutical is partnering with a global pharmaceutical company to help bring to market its investigative drug for cancer, PV-10, in mainland China, Hong Kong and Taiwan. The letter of intent with Boehringer Ingelheim comes weeks after the Knoxville clinical-stage oncology and dermatology biopharmaceutical company announced
7/7/15 - Qualification of BiomarkerPlasma Fibrinogen in Studies Examining Exacerbations and/or All-Cause Mortality for Patients With Chronic Obstructive...
SUMMARY: The Food and Drug Administration is announcing the availability of a draft guidance for industry entitled "Qualification of BiomarkerPlasma Fibrinogen in Studies Examining Exacerbations and/or All-Cause Mortality in Patients With Chronic Obstructive Pulmonary Disease." In the Federal Register of January 7, 2014, FDA announced the...
7/7/15 - Rare Diseases: The Pharmaceutical Landscape and Opportunity Areas
Dublin- Research and Markets has announced the addition of the "Rare Diseases: The Pharmaceutical Landscape and Opportunity Areas" report to their offering. The Rare Diseases: The Pharmaceutical Landscape and Opportunity Areas' report is a comprehensive study of the market of drugs being developed by the top pharmaceutical companies for rare diseas
7/7/15 - Researchers Submit Patent Application, "Process for Synthesis of Ezetimibe and Intermediates Used in Said Process", for Approval
By a News Reporter-Staff News Editor at Life Science Weekly From Washington, D.C., NewsRx journalists report that a patent application by the inventors Ding, Kuiling; Wang, Xiaoming; Wang, Zheng, filed on January 29, 2013, was made available online on June 25, 2015. No assignee for this patent application has been made. News editors obtained the
7/7/15 - Researchers Submit Patent Application, "Seizure Therapy", for Approval
By a News Reporter-Staff News Editor at Life Science Weekly From Washington, D.C., NewsRx journalists report that a patent application by the inventors Simeone, Kristina A.; Simeone, Timothy A., filed on June 12, 2013, was made available online on June 25, 2015. No assignee for this patent application has been made. Current FDA approved anti-epil
7/7/15 - US Pharma Companies Allocate $2.7 Million for Government Reimbursement Budgets, According to Pharmaceutical Intelligence Firm Cutting Edge Information
By a News Reporter-Staff News Editor at Journal of Technology Companies' budgets for government reimbursement activities either increased or remained constant between 2012 and 2014, according to a recent benchmarking study by pharmaceutical intelligence firm Cutting Edge Information. The study, "US Government Reimbursement: Winning Key Formulary.
7/6/15 - "Data Management and Delivery System for Health Care Applications" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Medvedeff, David; Li, Wuhong, filed on December 17, 2013, was made available online on June 25, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Vuca Health Holding
7/6/15 - "Pharmaceutical Composition Comprising 3-Beta-Hydroxy-5-Alpha-Pregnan-20-One with Improved Storage and Solubility Properties" in Patent Application...
"Pharmaceutical Composition Comprising 3- Beta-Hydroxy-5-Alpha-Pregnan-20-One with Improved Storage and Solubility Properties" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors BACKSTROM, Torbjorn; CARLSSON, Anders, filed on February 19, 2015, was made availa
7/6/15 - "Pharmaceutical Injection Device" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Murakami, Kenji; Fujimoto, Mitsuteru, filed on May 23, 2013, was made available online on June 25, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a comp
7/6/15 - Abbott Laboratories' Trademark Application for "TRUTORQ" Filed
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "TRUTORQ" by Elisa M. Valenzona, representing Abbott Laboratories. The owner/registrar information for this application is: Elisa M. Valenzona, Abbott Laborato
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415